| [1] |
Cooperberg MR, Zheng Y, Faino AV, et al. Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability[J]. JAMA Oncol, 2020, 6(10): e203187.
|
| [2] |
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422.
|
| [3] |
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2021, 385(12): 1091-1103.
|
| [4] |
Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial[J]. Lancet, 2018, 392(10162): 2353-2366.
|
| [5] |
Burdett S, Boeve LM, Ingleby FC, et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a stopcap systematic review and meta-analysis[J]. Eur Urol, 2019, 76(1): 115-124.
|
| [6] |
Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial[J]. Lancet, 2022, 399(10338): 1886-1901.
|
| [7] |
Fossati N, Willemse PM, Van den Broeck T, et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review[J]. Eur Urol, 2017, 72(1): 84-109.
|
| [8] |
Briganti A, Larcher A, Abdollah F, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores[J]. Eur Urol, 2012, 61(3): 480-487.
|
| [9] |
Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer[J]. J Urol, 2003, 170(5): 1798-1803.
|
| [10] |
Gandaglia G, Martini A, Ploussard G, et al. External validation of the 2019 briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection[J]. Eur Urol, 2020, 78(2): 138-142.
|
| [11] |
Gandaglia G, Ploussard G, Valerio M, et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies[J]. Eur Urol, 2019, 75(3): 506-514.
|
| [12] |
Hope TA, Eiber M, Armstrong WR, et al. Diagnostic accuracy of 68ga-psma-11 pet for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial[J]. JAMA Oncol, 2021, 7(11): 1635-1642.
|
| [13] |
Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)[J]. J Urol, 2021, 206(1): 52-61.
|
| [14] |
Shore ND, Saad F, Cookson MS, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer[J]. N Engl J Med, 2020, 382(23): 2187-2196.
|
| [15] |
Dearnaley DP, Saltzstein DR, Sylvester JE, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial[J]. Eur Urol, 2020, 78(2): 184-192.
|
| [16] |
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2×2 factorial design[J]. Lancet, 2022, 399(10336): 1695-1707.
|
| [17] |
Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial[J]. Future Oncol, 2022, 18(21): 2585-2597.
|
| [18] |
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial[J]. Lancet, 2010, 376(9747): 1147-1154.
|
| [19] |
Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study[J]. J Clin Oncol, 2020, 38(5): 395-405.
|
| [20] |
de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2020, 382(22): 2091-2102.
|
| [21] |
Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer[J]. JAMA, 2017, 317(11): 1141-1150.
|
| [22] |
Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer[J]. N Engl J Med, 2016, 375(15): 1425-1437.
|
| [23] |
Hoffman KE, Penson DF, Zhao Z, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer[J]. JAMA, 2020, 323(2): 149-163.
|
| [24] |
Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors[J]. N Engl J Med, 2008, 358(12): 1250-1261.
|
| [25] |
Szymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors[J]. Urology, 2010, 76(5): 1245-1250.
|
| [26] |
Esteva A, Feng J, van der Wal D, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials[J]. NPJ Digit Med, 2022, 5(1): 71.
|
| [27] |
Berchuck JE, Zhang Z, Silver R, et al. Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer[J]. Eur Urol, 2021, 80(3): 295-303.
|
| [28] |
Carter HB, Helfand B, Mamawala M, et al. Germline mutations in atm and brca1/2 are associated with grade reclassification in men on active surveillance for prostate cancer[J]. Eur Urol, 2019, 75(5): 743-749.
|
| [29] |
Halstuch D, Ber Y, Kedar D, et al. Short-term outcomes of active surveillance for low risk prostate cancer among men with germline dna repair gene mutations[J]. J Urol, 2020, 204(4): 707-713.
|